Clinical trial
Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients…
NCT00122304 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00122304 |
|---|---|
| Title | Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab |
| Official title | Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hemoglobinuria, Paroxysmal |
| Intervention type | Drug |
| Interventions | eculizumab |
| Enrollment | 85 |
| Start date | Dec 1, 2004 |
| Completion | Nov 1, 2006 |
| First posted | Jul 22, 2005 |
| Last update posted | Feb 21, 2007 |
| Countries | Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: